Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – Should You Buy?

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) gapped up prior to trading on Friday . The stock had previously closed at $85.02, but opened at $89.83. Structure Therapeutics shares last traded at $87.2790, with a volume of 442,416 shares trading hands.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Zacks Research downgraded shares of Structure Therapeutics from a “hold” rating to a “strong sell” rating in a report on Friday, October 17th. BMO Capital Markets reiterated an “outperform” rating on shares of Structure Therapeutics in a research report on Tuesday, January 6th. Citizens Jmp increased their price target on Structure Therapeutics from $87.00 to $120.00 and gave the stock a “market outperform” rating in a research report on Friday, December 12th. Morgan Stanley raised their price objective on Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Finally, Citigroup reiterated an “outperform” rating on shares of Structure Therapeutics in a research report on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $99.11.

Structure Therapeutics Stock Performance

The firm has a market cap of $5.41 billion, a P/E ratio of -72.90 and a beta of -2.05. The company’s 50 day moving average is $54.19 and its 200 day moving average is $33.58.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). On average, equities research analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Institutional Trading of Structure Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC lifted its position in shares of Structure Therapeutics by 530.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after purchasing an additional 901 shares during the period. State of Wyoming bought a new stake in Structure Therapeutics during the second quarter valued at $28,000. Assetmark Inc. grew its holdings in Structure Therapeutics by 39.9% during the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock worth $60,000 after acquiring an additional 820 shares during the period. ANTIPODES PARTNERS Ltd grew its holdings in Structure Therapeutics by 39.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after acquiring an additional 1,146 shares during the period. Finally, PNC Financial Services Group Inc. lifted its stake in shares of Structure Therapeutics by 29.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after purchasing an additional 994 shares during the period. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.